Medicinal Inorganic Chemistry: Metal‐containing Diagnostic Compounds
Published 2011 · Chemistry
Download PDFAnalyze on Scholarcy
Metallopharmaceuticals designed for use in diagnostic compounds cover a broad spectrum of diagnostic modalities, starting with barium sulfate for enhanced X-ray contrast, to the hugely successful gadolinium-based magnetic resonance imaging (MRI) contrast agents, to more recent advances in positron emission tomography (PET) and single photon emission computed tomography (SPECT) requiring radiolabeled metal-based diagnostic agents for image detection. In each case, the pharmacokinetics of tissue distribution and the thermodynamic stability of the metal-ligand coordination complex are very important to the clinical utility of the particular compound. For radiolabeling, the speed and ease of radiolabel production are also key features of the metallodiagnostic agent's utility. Keywords: MRI; contrast agent; SPECT; PET; rubidium; gadolinium; 64Cu; 68Ga; 67Ga; 18F; 99mTc; bifunctional metallopharmaceutical
This paper references
A lysine walk to high relaxivity collagen-targeted MRI contrast agents.
P. Caravan (2009)
A smart magnetic resonance contrast agent for selective copper sensing.
E. L. Que (2006)
High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging.
Eric J. Werner (2008)
pH-dependent modulation of relaxivity and luminescence in macrocyclic gadolinium and europium complexes based on reversible intramolecular sulfonamide ligation.
M. P. Lowe (2001)
A benzene-core trinuclear GdIII complex: towards the optimization of relaxivity for MRI contrast agent applications at high magnetic field.
J. B. Livramento (2008)
Relaxivity of MRI Contrast Agents
É. Tóth (2002)
New Classes of MRI Contrast Agents
Vincent Jacques (2002)
Multilocus binding increases the relaxivity of protein-bound MRI contrast agents.
Z. Zhang (2005)
Magnetic resonance contrast enhancement of neovasculature with αvβ3‐targeted nanoparticles
S. Anderson (2000)
The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates.
P. Caravan (2002)
Lanthanide(III) chelates for NMR biomedical applications
S. Aime (1998)
Design of targeting ligands in medicinal inorganic chemistry.
T. Storr (2006)
Mechanistic studies of a calcium-dependent MRI contrast agent.
W. Li (2002)
Radiometal-Labeled Agents (Non-Technetium) for Diagnostic Imaging
C. Anderson (1999)
Water-soluble contrast agents targeted at the estrogen receptor for molecular magnetic resonance imaging.
C. Gunanathan (2007)
Next generation, high relaxivity gadolinium MRI agents.
K. Raymond (2005)
Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease.
R. Stewart (1991)
Gadolinium(III) 1,2-hydroxypyridonate-based complexes: toward MRI contrast agents of high relaxivity.
J. Xu (2004)
Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C
T. Frenzel (2008)
Determinants of the response of left ventricular ejection fraction to vasodilator stress in electrocardiographically gated 82rubidium myocardial perfusion PET
T. Brown (2007)
Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent.
P. Caravan (2007)
Cell-permeable MR contrast agents with increased intracellular retention.
Paul J H Endres (2008)
In vivo visualization of gene expression using magnetic resonance imaging
A. Louie (2000)
Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis.
M. Perazella (2008)
Radiohalogens for imaging and therapy.
M. Adam (2005)
Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia.
A. Vāvere (2007)
EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus.
Kirsten Overoye-Chan (2008)
[GdPCP2A(H2O)2]-: A Paramagnetic Contrast Agent Designed for Improved Applications in Magnetic Resonance Imaging
S. Aime (2000)
An investigation of the toxicity of gadolinium based MRI contrast agents using neutron activation analysis.
M. E. Bartolini (2003)
Multimodal MRI contrast agents
Luca Frullano (2007)
Potentiometric and relaxometric properties of a gadolinium-based MRI contrast agent for sensing tissue pH.
Ferenc K Kálmán (2007)
Toward optimized high-relaxivity MRI agents: the effect of ligand basicity on the thermodynamic stability of hexadentate hydroxypyridonate/catecholate gadolinium(III) complexes.
D. M. Doble (2003)
Biomedical uses and applications of inorganic chemistry. An overview
Nicholas Farrell (2002)
Current use and future potential of organometallic radiopharmaceuticals
R. Schibli (2002)
Solution structure and dynamics of lanthanide(III) complexes of diethylenetriaminepentaacetate: a two-dimensional NMR analysis
B. Jenkins (1988)
Use of lanthanide-grafted inorganic nanoparticles as effective contrast agents for cellular uptake imaging.
P. Voisin (2007)
Molecular imaging with PET.
S. Ametamey (2008)
Toward improved syntheses of dendrimer-based magnetic resonance imaging contrast agents: new bifunctional diethylenetriaminepentaacetic acid ligands and nonaqueous conjugation chemistry.
H. Xu (2007)
Gadolinium complex of tris[(3-hydroxy-1-methyl- 2-oxo-1,2-didehydropyridine-4-carboxamido)ethyl]-amine: A New Class of gadolinium magnetic resonance relaxation agents
J. Xu (1995)
Synthesis and biodistribution of lipophilic and monocationic gallium radiopharmaceuticals derived from N,N'-bis(3-aminopropyl)-N,N'-dimethylethylenediamine: potential agents for PET myocardial imaging with 68Ga.
Yui-May Hsiao (2009)
Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes.
P. Hermann (2008)
Strategies for increasing the sensitivity of gadolinium based MRI contrast agents.
P. Caravan (2006)
Toward optimized high-relaxivity MRI agents: thermodynamic selectivity of hydroxypyridonate/catecholate ligands.
V. C. Pierre (2004)
The biomedical chemistry of technetium and rhenium
J. R. Dilworth (1998)
A new bisphosphonate-containing 99mTc(I) tricarbonyl complex potentially useful as bone-seeking agent: synthesis and biological evaluation
E. Palma (2007)
Bioresponsive, cell-penetrating, and multimeric MR contrast agents.
Jody L. Major (2009)
An unusual dimeric structure of a Cu(I) bis(thiosemicarbazone) complex: implications for the mechanism of hypoxic selectivity of the Cu(II) derivatives.
A. Cowley (2002)
The effect of ligand scaffold size on the stability of tripodal hydroxypyridonate gadolinium complexes.
B. O'sullivan (2003)
Image Formation by Induced Local Interactions: Examples Employing Nuclear Magnetic Resonance
P. Lauterbur (1973)
Benefiting from the unique properties of lanthanide ions.
Jean-Claude G Bünzli (2006)
Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals.
S. Liu (2001)
Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI.
S. Young (1996)
Collagen-targeted MRI contrast agent for molecular imaging of fibrosis.
P. Caravan (2007)
Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design
R. Lauffer (1987)
99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals.
S. Liu (1999)
Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. insights into mechanisms of copper uptake and hypoxia selectivity.
Z. Xiao (2008)
Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy.
J. Sessler (2000)
Metals in Medicine.
Zijian Guo (1999)
Syntheses and relaxation properties of mixed gadolinium hydroxypyridinonate MRI contrast agents.
S. Cohen (2000)
All Science Is Interdisciplinary—From Magnetic Moments to Molecules to Men (Nobel Lecture)
Paul C. Lauterbur (2005)
Insights into the use of paramagnetic Gd(III) complexes in MR‐molecular imaging investigations
S. Aime (2002)
Coordination compounds in nuclear medicine
S. Jurisson (1993)
The relationship between thermodynamics and the toxicity of gadolinium complexes.
W. Cacheris (1990)
1,2-hydroxypyridonate/terephthalamide complexes of gadolinium(III): synthesis, stability, relaxivity, and water exchange properties.
Eric J. Werner (2009)
99m-Technetium carbohydrate conjugates as potential agents in molecular imaging.
M. Bowen (2008)
Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications.
P. Caravan (1999)
Metal complexes of maltol and close analogues in medicinal inorganic chemistry.
K. Thompson (2006)
Quantitative Imaging of Cell-Permeable Magnetic Resonance Contrast Agents Using X-Ray Fluorescence
Paul J H Endres (2006)
New magnetic resonance contrast agents as biochemical reporters
T. Meade (2003)
Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.
T. Wadas (2010)
Dissociation of gadolinium chelates in mice: relationship to chemical characteristics.
P. Wedeking (1992)
A glucosamine-dipicolylamine conjugate of 99mTc(I) and 186Re(I) for use in imaging and therapy.
T. Storr (2005)
Potential technetium small molecule radiopharmaceuticals.
S. Jurisson (1999)
99mTc-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer.
Jiyun Shi (2008)
Carbohydrate conjugates for molecular imaging and radiotherapy: 99mTc(I) and 186Re(I) tricarbonyl complexes of N-(2'-Hydroxybenzyl)-2-amino-2-deoxy-D-glucose.
S. Bayly (2004)
Tris(pyrone) chelates of Gd(III) as high solubility MRI-CA.
D. Puerta (2006)
Metal-Based X-ray Contrast Media.
S. Yu. (1999)